Related Experiment Videos
Effect of vanadium on insulin sensitivity and appetite
J Wang1, V G Yuen, J H McNeill
1Division of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada.
Metabolism: Clinical and Experimental
|June 9, 2001
Summary
Bis(maltolato)oxovanadium(IV) (BMOV) reduced appetite and body fat in insulin-resistant rats by lowering hypothalamic neuropeptide Y (NPY) and increasing leptin sensitivity, suggesting potential obesity therapeutics.
Area of Science:
- Biochemistry
- Endocrinology
- Neuroscience
Background:
- Vanadium compounds mimic insulin's metabolic actions.
- The mechanism of vanadium's effect on appetite and weight in insulin-resistant rats is unclear.
- Insulin influences appetite via hypothalamic neuropeptide Y (NPY) and leptin secretion.
Purpose of the Study:
- To investigate if vanadium's appetite-reducing effects are linked to altered hypothalamic NPY levels.
- To examine vanadium's impact on leptin secretion and sensitivity.
- To assess the therapeutic potential of bis(maltolato)oxovanadium(IV) (BMOV) in obesity.
Main Methods:
- Chronic administration of BMOV to Zucker lean and fatty rats.
- Measurement of plasma and adipose tissue leptin levels.
- Quantification of hypothalamic NPY mRNA and peptide levels using in situ hybridization and immunocytochemistry.
Main Results:
- BMOV treatment reduced food intake, body fat, body weight, plasma insulin, and glucose levels in fatty rats.
- BMOV enhanced insulin-induced elevations in circulating and adipose leptin levels.
- BMOV decreased hypothalamic NPY mRNA and peptide levels in the arcuate nucleus and paraventricular nucleus.
Conclusions:
- BMOV may enhance insulin sensitivity in adipose tissue.
- BMOV appears to decrease appetite and body fat by reducing hypothalamic NPY levels.
- BMOV shows promise as a therapeutic agent for obesity due to its effects on appetite and weight regulation.